DCM
DAFNA Capital Management Portfolio holdings
AUM
$362M
This Quarter Return
-22.69%
1 Year Return
-0.48%
3 Year Return
+117.01%
5 Year Return
+181.93%
10 Year Return
+1,483.26%
AUM
$116M
AUM Growth
+$116M
(+3.3%)
Cap. Flow
+$13.8M
Cap. Flow
% of AUM
11.87%
Top 10 Holdings %
Top 10 Hldgs %
40.13%
Holding
99
New
22
Increased
22
Reduced
12
Closed
5
Top Buys
| 1 |
VTAE
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
|
$3.94M |
| 2 |
DERM
Dermira, Inc.
DERM
|
$3.55M |
| 3 |
Neurocrine Biosciences
NBIX
|
$3.02M |
| 4 |
ALDR
Alder Biopharmaceuticals, Inc.
ALDR
|
$3M |
| 5 |
Novavax
NVAX
|
$2.86M |
Top Sells
| 1 |
WINT
Windtree Therapeutics Inc
WINT
|
$11.6M |
| 2 |
CRDC
CARDICA INC COM NEW (DE)
CRDC
|
$4.49M |
| 3 |
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
|
$3.93M |
| 4 |
Riot Platforms
RIOT
|
$1.41M |
| 5 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
$725K |
Sector Composition
| 1 | Healthcare | 73.43% |
| 2 | Financials | 0.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
AtriCure
ATRC
$1.84B
| $8.22M | 7.09% | 488,446 +500 | +0.1% | +$8.42K |
|
2
AbbVie
ABBV
$372B
| $6.66M | 5.74% | 116,581 | – | – |
|
|
NXTM
3
DELISTED
NxStage Medical Inc.
NXTM
| $5.94M | 5.13% | 396,554 +30,000 | +8% | +$450K |
|
|
VTAE
4
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
| $5.22M | 4.5% | 787,373 +594,149 | +307% | +$3.94M |
|
5
Rigel Pharmaceuticals
RIGL
$697M
| $3.9M | 3.37% | 1,876,492 +766,752 | +69% | +$1.59M |
|
|
DERM
6
DELISTED
Dermira, Inc.
DERM
| $3.55M | 3.07% | +171,881 | New | +$3.55M |
|
7
Insulet
PODD
$23.9B
| $3.52M | 3.03% | 106,018 | – | – |
|
|
ALDR
8
DELISTED
Alder Biopharmaceuticals, Inc.
ALDR
| $3.44M | 2.96% | 140,313 +122,313 | +680% | +$3M |
|
|
MRNS
9
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $3.05M | 2.63% | 566,498 | – | – |
|
|
10
Neurocrine Biosciences
NBIX
$13.8B
| $3.02M | 2.6% | +76,300 | New | +$3.02M |
|
|
11
Novavax
NVAX
$1.21B
| $2.86M | 2.46% | +553,500 | New | +$2.86M |
|
|
BEAT
12
DELISTED
BioTelemetry, Inc.
BEAT
| $2.75M | 2.37% | 235,645 | – | – |
|
13
Galapagos
GLPG
$2.07B
| $2.74M | 2.37% | 65,568 +35,568 | +119% | +$1.49M |
|
|
RGLS
14
DELISTED
Regulus Therapeutics
RGLS
| $2.71M | 2.34% | 391,500 +301,500 | +335% | +$2.09M |
|
|
AGTC
15
DELISTED
Applied Genetic Technologies Corporation
AGTC
| $2.34M | 2.02% | 167,192 +10,000 | +6% | +$140K |
|
|
AERI
16
DELISTED
Aerie Pharmaceuticals, Inc.
AERI
| $2.19M | 1.89% | 179,769 +31,400 | +21% | +$382K |
|
17
Masimo
MASI
$7.59B
| $1.93M | 1.66% | 46,010 | – | – |
|
18
uniQure
QURE
$896M
| $1.89M | 1.63% | 158,907 +123,907 | +354% | +$1.47M |
|
|
ACHN
19
DELISTED
Achillion Pharmaceuticals, Inc.
ACHN
| $1.83M | 1.58% | 236,500 | – | – |
|
|
TVRD
20
Tvardi Therapeutics, Inc. Common Stock
TVRD
$281M
| $1.66M | 1.43% | 267,046 +97,715 | +58% | +$608K |
|
21
iShares Biotechnology ETF
IBB
$5.6B
| $1.57M | 1.35% | +6,000 | New | +$1.57M |
|
22
Stereotaxis
STXS
$261M
| $1.51M | 1.3% | 1,372,862 | – | – |
|
|
BSTC
23
DELISTED
BioSpecifics Technologies Corp.
BSTC
| $1.38M | 1.19% | +39,704 | New | +$1.38M |
|
24
Xenon Pharmaceuticals
XENE
$2.98B
| $1.35M | 1.16% | 193,195 +95,465 | +98% | +$667K |
|
|
RDUS
25
DELISTED
Radius Health, Inc.
RDUS
| $1.34M | 1.16% | +42,600 | New | +$1.34M |
|